CS
IMVT icon

Candriam SCA’s Immunovant IMVT Stock Holding History

Candriam SCA’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-680,372
Closed -$16.9M – 706
2026
Q1 		$16.9M Hold
680,372
– – 0.09% 214
2025
Q4 		$17.3M Buy
+680,372
New +$15.2M 0.09% 206
2021
Q2 		– Sell
-181,749
Closed -$8.06M – 918
2021
Q1 		$8.06M Hold
181,749
– – 0.07% 290
2020
Q4 		$8.39M Sell
181,749
-38,251
-17% -$1.77M 0.07% 298
2020
Q3 		$7.74M Buy
220,000
+80,000
+57% +$2.41M 0.07% 274
2020
Q2 		$3.41M Buy
+140,000
New +$3M 0.04% 404

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Candriam SCA's IMVT Position: Q2 2026 in Review

Candriam SCA sold out of Immunovant (IMVT) in Q2 2026, closing a stake of 680,372 shares — an estimated $16.9M sold.

Candriam SCA first reported a position in IMVT in Q2 2020 and held it in 6 quarters. The position peaked at $17.3M in Q4 2025. 227 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Candriam SCA reported no remaining Immunovant position as of Q2 2026 after selling out during the quarter.
  • Candriam SCA sold 680,372 Immunovant shares in Q2 2026, an estimated $16.9M.
  • Candriam SCA first reported a position in Immunovant in Q2 2020 and held it in 6 quarters.
  • Candriam SCA's Immunovant position peaked at $17.3M in Q4 2025.
  • 227 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.